Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Closes Second Financing Round; Undisclosed Amount Higher Than Series A

NEW YORK, Oct. 11 (GenomeWeb News) - Dutch diagnostics firm Agendia has closed a second round of financing worth "double-digit" millions of dollars to accelerate the development of microarray-based late-stage products into diagnostic tests, the company said today.

 

An Agendia spokesperson declined to provide a specific amount, but said that the financing improved upon the company's Series A round, which closed in March 2004.

 

The financing round was led by existing investors Gilde, AXA, and GLSV, and new investor Van Herk Group.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.